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I. INTRODUCTION
In the aftermath of the 2002 Johannesburg World Summit
on Sustainable Development,1 countries around the world
struggle to harmonize their national legislation 2 with Agenda
1 See World Summit on Sustainable Development, at http://www.johannes-
burgsummit.org/html/basicinfo?basicinfo.html (last visited Aug. 10, 2002) (report-
ing that the Johannesburg Summit took place from August 26 to September 4,
2002, and focused on conservation of natural resources). See also Paula Stober,
Summit Holds Hope for Saving the Planet, NEWS & RECORD, Aug. 6, 2002, at A10
(mentioning that the 2002 World Summit evaluated developments since the 1992
Rio Earth Summit), LEXIS, News Group File; Michael Hanlon, Commentary,
DAILY MAIL, Aug. 7, 2002 (suggesting that the 1992 Earth Summit only resulted in
political debates and that biodiversity today is decreasing at a faster rate than ten
years ago), LEXIS, News Group File; James Lamont & John Mason, A Long Way to
Go for a Little Success, FIN. TIMES (LONDON), Sept. 4, 2002 (noting that the summit
only achieved a limited success in the area of biodiversity protection), LEXIS,
News Group File. See generally Barry James, Summit Aims, Again, for a Better
World; Lofty Goals, Sorry Record, INT'L HERALD TRIB., Aug. 8, 2002, at 1 (expres-
sing an opinion that the results since the 1992 Earth Summit are disappointing
and that environmental degradation nowadays is much worse than ten years ago),
LEXIS, News Group File.
2 See Mario Osava, Environment-Brazil: From Pariah to World Conservation
Leader, INTER PRESS SERVICE, June 6, 2002 (explaining that Brazil seeks to rein-
force its leadership in the area of biodiversity and to stay behind the commitments
it made ten years ago in Rio de Janeiro), LEXIS, News Group File. See also S. K.
Verma, Biodiversity and Intellectual Property Rights, CASRIP NEWSLETTER (Uni-
[Vol. 15:247
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21 ("the Agenda"),3 the Convention on Biological Diversity
("CBD"), 4 and the Agreement on Trade-Related Aspects of Intel-
lectual Property Rights ("TRIPS").5 Brazil is one such example
where 20,000 medicinal plant samples disappear from the Bra-
zilian rainforest every year due to the absence of permanent na-
tional legislation regulating access to medicinal herbs.6
Bioprospecting7 flourishes and professional scientists prefer not
to conduct trials in Brazil, which delays the development of new
drugs of global significance. 8 Thus, it is not a surprise that
while Brazil owns about half of the world medicinal plant re-
versity of Washington School of Law/CASRIP, Seattle, WA), Spring 2000, at 1-2
(declaring that all members of the CBD and TRIPS face the problem of compli-
ance), at http://www.law.washington.edu/casrip/newsletter/newsv7i2Verma.pdf
(last visited Aug. 7, 2002).
3 See U.N. Conference on Environment and Development, Agenda 21, U.N.
Doc. A/Conf.151/26/Rev.1 (1992) (noting the importance of environmental conser-
vation and the role of indigenous people for sustainable development), at http://
www.un.org/ esa/sustdev/agenda2l.htm (last visited Aug. 7, 2002).
4 See U.N. Convention on Biological Diversity, June 5, 1992, U.N. Doc. DPI/
1307 (1992) [hereinafter CBD (emphasizing the ownership of every country over
its own natural resources and the importance of intellectual property law to pre-
serve natural resources), at http://www.biodiv.org/convention/articles.asp (last vis-
ited Aug. 6, 2002). See generally Carrie Smith, Patenting Life: The Potential and
the Pitfalls of Using the WTO to Globalize Intellectual Property Rights, 26 N.C.J.
INT'L L. & COM. REG. 143, 152 (2000) (providing an analytical overview of the CBD
such as seen by developed and developing countries).
5 See Agreement on Trade-Related Aspects of Intellectual Property Rights,
Apr. 15, 1994, Marrakesh Agreement Establishing the World Trade Organization,
Annex 1C, 33 I.L.M. 1197 (1994) [hereinafter TRIPS] (defining the minimal stan-
dards of intellectual property protection).
6 See EMBASSY OF BRAZIL, SUSTAINABLE AMAZON, Summer 2000 (assessing
that every year 20,000 extracts leave Brazil), at http://www.brasilemb.org/environ-
sustainable_ amazon.shtml (last visited Aug. 7, 2002).
7 See Valentina Tejera, Tripping Over Property Rights: Is it Possible to Rec-
oncile the Convention on Biological Diversity with Article 27 of the TRIPS Agree-
ment, 33 NEW ENG. L. REV. 967, 971 (1999) (defining biodiversity as a search by
professional botanists and shamans for biological resources for pharmaceutical
use, or a "gene hunting," that results in treatments for diseases such as cancer).
8 See MINISTRY OF THE ENVIRONMENT, FIRST NATIONAL REPORT FOR THE CON-
VENTION ON BIOLOGICAL DwERsITY-BRAZIL 159 (1999) [hereinafter FIRST NATIONAL
REPORT OF BRAZIL] (revealing that the main reason for biopiracy in Brazil is the
lack of permanent law on access to genetic resources and benefit-sharing), availa-
ble at www.biodiv.org/doc/world/br/br-nr-01-p9-en.pdf (last visited Aug. 9, 2002).
See also Estela Viana, Brazil's Biodiversity Attracts More Interest, GAZETA MER-
CANTIL, June 1, 2001 (explaining that the fauna and flora in Brazil may be worth
$4 trillion), LEXIS, Major World Newspapers.
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sources, the country benefits the least from the commercial
transformation of plants into pharmaceuticals.9
At the same time, Switzerland has twenty times fewer me-
dicinal plants than Brazil, but benefits the most out of any
country from the commercialization of plants. 10 Switzerland
implemented guidelines for access to medicinal plant re-
sources," ecotourism, 12 and regulation of its endangered
flora. 13 Switzerland also adopted the "Swiss claim"' 4 in its pat-
9 See Ana Paula Corazza, Bio Plunderers, BRAZIL, Mar. 2001, (specifying that
of the 240,000 species of plants with flowers in the world, 150,000 are in the trop-
ics, and of these, 55,000 are on the territory of Brazil), at http://www.brazzil.com/
p24mar01.htm (last visited Aug. 10, 2002). See also Larry Rohter, Brazil's Tribes
Seek Jungle-Plant Profits, PITTSBURGH POST-GAzETrE, Dec. 31, 2001 (stating that
many of those plants grow only in Brazil and indigenous people have used them to
treat various diseases), 2001 WL 28685712; FIRST NATIONAL REPORT OF BRAZIL,
supra note 8, at 12 (declaring that Brazil is the richest megadiversity country and
has about twenty-two percent of the world's plants). See generally EMBASSY OF
BRAZIL, KEY FACTS 1 (providing statistics about Brazil's investment in scientific
research and development), at www.brasilemb.org/tech2.shtml (last visited Aug. 6,
2002).
10 See A. Cunningham, Ethics, Biodiversity, and New Natural Products Devel-
opment, PEOPLE AND PLANTS ONLINE (Apr. 1993) (comparing biodiverse countries
with countries that benefit the most from the commercialization of their natural
resources), available at http://www.rbgkew.org.uk/peopleplants/dp/dp2 (last vis-
ited Aug. 7, 2002).
11 See Draft Guidelines of Switzerland on Access and Benefit Sharing Regard-
ing the Utilization of Genetic Resources, Oct. 30 - Nov. 1, 2000 [hereinafter Swiss
Guidelines] (outlining important measures to ensure the proper preservation and
access to natural resources), at http://www.unctad.org/tradeenv/ docs/swiss.pdf
(last visited Aug. 7, 2002).
12 See D. J. De Villier, Beyond Attractive Destinations, WORLD SURFACE.COM
(July 30, 2001) (defining ecotourism as a type of tourism where tourists visit places
and pay special attention to the preservation of the environment, and stating that
it is a powerful source for creating more jobs, combating poverty, and protecting
the natural and cultural environment), at http://www.worldsurface.com/browse/
static.asp?staticpageid=1084 (last visited Aug. 10, 2002).
13 See Swiss Agency for the Environment, Forests and Landscape, Swiss
Clearing-House Mechanism Biodiversity: Switzerland at a Glance/ Red Lists/ In-
troduction (1998) (describing the purpose and impact of the red lists of endangered
plant species), available at http://www.buwal.ch/nachh/chmi/e/ch/problems/redin-
tro.htm (last visited Aug. 10, 2002).
14 See Loi f~d~rale du 25 juin 1954 sur les brevets d'invention, Legge federale
del 25 giugno 1954 sui brevetti d'invenzione, Bundesgesetz vom 25. Juni 1954 iber
die erfindungspatente [Switzerland Federal Law on Patents for Inventions], RO
1955 893, RU 1955 899, AS 1955 871, art. 7(c) (1954) (amended 1995) (defining
"Swiss type" claims as compounds subject of a prior right, which do not meet these
conditions with respect to their use for the implementation of a method of thera-
peutic treatment or diagnosis constitute new substances to the extent that they
are intended solely for such use, and such patent is known as a "Swiss claim" or
4http://digitalcommons.pace.edu/pilr/vol15/iss1/8
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ent law, which is a claim for new therapeutic uses of known
molecules, and continues to rely on ethnobiological
knowledge. 15
This comment compares the existing national laws for me-
dicinal plant protection in Brazil and Switzerland. It recom-
mends that Brazil adopt the "Swiss claim" model for patent
protection and make provisionary laws on access to genetic re-
sources less stringent. 16 This comment further recommends
that Brazil incorporate sustainable ecotourism guidelines into
its draft law on access to genetic resources and introduce the
red and blue book listing of endangered herbs.' 7
Part I presents the international legal framework for the
protection of biodiversity and enforcement of intellectual prop-
erty rights.' 8 Part I also discusses the implementation of the
relevant international treaties in Brazil and Switzerland.' 9
Part II analyzes, first, why Brazil has much to learn from Swit-
zerland and, second, what the basis for comparison is between
the two countries. 20 Then, Part III recommends that Brazil
adopt the type of intellectual property and environmental legal
"Swiss type" claim), available at http://clea.wipo.int/clea/lpext. dll?f=templates&
fn=main-hit-h.htm&2.0 (last visited Aug. 10, 2002).
15 See Gelvina Stevenson, Trade Secrets: The Secret to Protecting Indigenous
Ethnobiological (Medicinal) Knowledge, 32 N.Y.U. J. INT'L & POL. 1119, 1132
(2000) (defining ethnobiological knowledge as knowledge belonging to indigenous
people, where indigenous people can draw attention to a specific plant, describe
the specific part of the plant that contains the medical substance, identify the time
of the year when the substance is present, explain the physiological effects of that
plant, describe the method of preparing the substance, and thus provide valuable
clues to the identity of active molecules and expedite their isolation in the
laboratory).
16 See infra notes 173-84, 194-200 and accompanying text (recommending
that Brazil make its medicinal plants more accessible to scientists and adopt the
"Swiss claim" approach).
17 See infra notes 184-93, 201-11 and accompanying text (discussing that Bra-
zil should incorporate ecotourism guidelines into its draft law and that red-listing
should be a good approach).
18 See infra notes 23-32, 60-73 and accompanying text (outlining the interna-
tional laws for the protection of biodiversity and intellectual property).
19 See infra notes 33-59, 74-91 and accompanying text (describing how Brazil
and Switzerland implemented the international laws on biodiversity and intellec-
tual property protection into their national legislation).
20 See infra notes 101-37 and accompanying text (comparing the constitu-
tional and ethnobiological traditions in Brazil and Switzerland).
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protection already in place in Switzerland. 21 Finally, the com-
ment concludes in favor of the Swiss model for the protection of
medicinal plant resources in Brazil.22
II. BACKGROUND
This background section outlines the international frame-
work for environmental protection of pharmaceutical biodivers-
ity and its implementation in Brazil and Switzerland
respectively. The section also describes TRIPS and its national
implementation in each of the two countries.
A. Environmental Protection of Pharmaceutical Biodiversity
1. International Framework: Agenda 21 and CBD
Agenda 21 and the CBD contain provisions to assist coun-
tries in the implementation of national legislation against bi-
opiracy. 23 The Agenda encourages commercial use of natural
resources and the protection of ethnobiological traditional
knowledge 24 through intellectual property. 25 It propagates a
conservation of biological diversity and a sustainable use of bio-
logical resources. 26 The Agenda views biological resources as
21 See infra notes 173-211 and accompanying text (suggesting that Brazil
make its biodiversity legislation less stringent, adopt the "Swiss claim" patents
and implement the red listing system).
22 See infra notes 212-18 and accompanying text (concluding favorably on the
implementation of the Swiss model in Brazil).
23 See Graham Dutfield, Developing and Implementing Systems for Protecting
Traditional Knowledge: A Review of Experiences in Selected Developing Countries,
at 8 (defining biopiracy as an unauthorized extraction of biological resources or
associated biological knowledge from developing countries), available at http:l!
www.unctad.org/tradeenv/tk.htm (last visited Aug. 10, 2002). See also Michael
Gollin & Sarah Laird, Global Policies, Local Actions: The Role of National Legisla-
tion in Sustainable Biodiversity Prospecting, 2 B.U. J. Sci. & TECH. L. 16, para. 15
(1996) (highlighting that the best and only possible way to deal with global
problems is through adequate laws and regulations).
24 See CBD, supra note 4 (defining traditional knowledge as "knowledge, inno-
vations and practices of indigenous and local communities embodying traditional
lifestyles" in article 8()). Id.
25 See David R. Downes, How Intellectual Property Could be a Tool to Protect
Traditional Knowledge, 25 COLUM. J. ENV'L. L. 253, 281 (2000) (concluding that
intellectual property use in accordance to the development needs of developing
countries could protect their biological knowledge).
26 See Agenda 21, supra note 3, ch. 15 (stating that the natural ecosystems
contain most of Earth's biodiversity and that biological resources provide
medicines, and that the current decline in biodiversity is a serious threat to human
6http://digitalcommons.pace.edu/pilr/vol15/iss1/8
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an important asset to yield sustainable benefits and emphasizes
states' sovereign rights over their own natural resources. 27
Moreover, the Agenda recognizes that cooperation between
scientists and industries could result in a transfer of technology
to improve human health.28
The CBD calls for conservation and sustainable develop-
ment of biodiversity, fair benefit-sharing, and absolute control
of developing countries over their natural resources. 29 The
development). See also id. ch. 2 (noting that environment and trade policies should
be mutually supportive and that governments should meet those objectives
through multilateral forums).
27 See id. ch. 15 (highlighting that developing countries have control over
their biological resources and must benefit from the biotechnological development
and commercial utilization of the products derived from their national resources,
and that those goals could be achieved through a broader regional and interna-
tional cooperation). See also id. ch. 26 (clarifying that governments around the
world should incorporate the rights and responsibilities of indigenous people in
their national legislation); Tanja Sturm, Government Launches Bid to Discover
New Herbal Medicine, WORLD MARKETS RESEARCH CENTRE, Feb. 26, 2002 (observ-
ing that the World Health Organization states there are 250,000 species of medici-
nal plants in the developing world and that those plants' extracts are the source of
"more than eighty-five percent of the medicines used by eighty percent of the popu-
lation in the developing world"), LEXIS, Major World Newspapers.
28 See Agenda 21, supra note 3, ch. 16 (stating the necessity for training and
technology transfer in the developing world).
29 See Press Release, U. N. Convention on Biological Diversity, International
Day for Biological Diversity Dedicated to Forest Biodiversity (May 22, 2002) (de-
claring that forests are vital for human health and other economic benefits), at
www.biodiv.org/ doc/press/pr-2002-05-02-ibd-en.pdf (last visited Aug. 5, 2002). See
also U.N. Conference for Trade and Development, The Biotrade Initiative (high-
lighting that the world production of natural ingredients for cosmetics has been
estimated at $1 billion, out of which fifty-five percent is derived from developing
countries, and that ecotourism is becoming important within the tourism industry
generating more than $260 billion per year), at http://www.biotrade.org/Quick
Place/biotrade/ Main.nsf/h_B4BD9585D70EA32CC 1256C0000352A94/5d978e894a
aaa092c1256c0000352aba/!OpenDocument (last visited Aug. 10, 2002); CBD,
supra note 4, art. 1 (establishing that the objectives of the CBD are the conserva-
tion of biological diversity, the sustainable use of its components, and the fair and
equitable sharing of the benefits arising out of the utilization of genetic resources);
Id. art. 15 (declaring the importance of sharing the benefits from the commercial
utilization of genetic resources); Vandana Date, Global "Development" and the En-
vironmental Ramifications- The Interlinking of Ecologically Sustainable Develop-
ment and Intellectual Property Rights, 27 GOLDEN GATE U.L. REV. 631, 631 (1997)
(describing the link between biodiversity and intellectual property rights in the
CBD). See generally Amy Guerin Thompson, An Untapped Resource in Addressing
Emerging Infectious Diseases: Traditional Healers, 6 IND. J. GLOBAL LEG. STUD.
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CBD also recognizes the interest of developing countries in pro-
tecting their natural resources, the preservation of indigenous
cultures, 30 and the transfer of technology.31 The CBD ad-
dresses the importance of intellectual property rights to protect
biodiversity in that proper intellectual property protection facil-
itates the transfer of technology and sharing of ethnobiological
traditions. 32 In sum, the Agenda and CBD propagate access to
genetic material against fair compensation and respect for
ethnobiological knowledge.
2. National Implementation in Brazil
Although Brazil was the first country in the world to sign
the CBD,33 it has failed to update its law regulating access to
biological diversity in compliance with the CBD and the
Agenda. 34 The country has adopted various decrees, but lacks a
permanent law regulating access to pharmaceutical biodivers-
ity. In 1969, Brazil adopted a temporary decree that addressed
access to biodiversity. 35 It established the Science Council,
which is responsible for authorizing and supervising foreign sci-
entific expeditions to explore the Amazon. 36 The Ministry of
Science and Technology inspects and retains all materials col-
lected by foreigners.37 In 1990, Brazil implemented a decree
30 See CBD, supra note 4, art. 8(j) (stating the importance of indigenous peo-
ple and their cultures for sustainable development).
31 See id. art. 16 (stating that access and transfer of environmentally sound
technology among contracting parties are essential for the conservation and sus-
tainable use of biological diversity); Id. arts. 20-21 (remarking that developed
countries shall provide financial resources to enable developing countries to meet
the costs of implementation of the CBD).
32 See CBD, supra note 4, arts. 15 -16, 19 (addressing respectively the issue of
access to genetic resources, the access and transfer to technology, and the handling
and distribution of benefits to developing countries).
33 See FIRST NATIONAL REPORT OF BRAZIL, supra note 8, at 159 (stating that
Brazil signed the Convention on Biological Diversity during the United Nations
Conference on Environment and Development in Rio de Janeiro in June 1992).
34 See id. (discussing Decree No.65.057 from August 26, 1969 as it relates to
access to genetic material in Brazil).
35 See id.
36 See id. (stating that the decree No. 65.057 from August 1969 established
the norms for scientific expeditions in Brazil).
37 See id. (reporting that collected materials include pressings, photographs,
and drawings of the scientific material).
[Vol. 15:247
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that required an advance authorization to export biological ma-
terial outside the territory of Brazil. 38
In 1995, Brazil drafted a law that the Brazilian Senate has
yet to ratify.39 The Draft Law requires prior consent from the
indigenous people over access to their territories and fair com-
pensation for the utilization of genetic resources.40 According to
the Draft Law, Brazil has national sovereignty over its genetic
resources 41 and the federal government has the sole authority
to grant access to the country's medicinal plants.4 2 The proce-
dure to obtain permission is long and complex and requires de-
tailed documentation. 43  The permission limits research
38 See id. at 158 (discussing that decree No. 98,830 from January 15, 1990,
legislates on the collection of scientific material by foreigners).
39 See FIRST NATIONAL REPORT OF BRAZIL, supra note 8, at 159 (discussing
that Bill of Law No. 306/95 still has not become a permanent law). See also Brazil
Sees Promise in Jungle Plants, But Tribes See Peril, Dec. 23, 2001 (discussing that
since permanent legislation is absent, the Brazilian government has issued several
temporary decrees to regulate research, and remarking that in the absence of per-
manent legislation, many foreign research institutions hesitate to sign cooperation
contracts, especially after a contract between a government-controlled institution
and the pharmaceutical company Novartis failed in 2000), at http://senrs.com/bra-
zil%20_seespromise-injungle-plants.htm (last visited Aug. 5, 2002); Greg
Brown, Holding Pattern, LATINTRADE.COM, Health & Medicine Section, (Nov. 2001)
(discussing a deal with Novartis in which they were to spend 4 million on research
programs in Brazil and in return they would be permitted to ship 10,000 gene
samples to its Basel headquarters; however, the contract was later denounced and
Novartis was accussed of biopiracy), at http://www.latintrade.comlnewsite/content/
archives.cfm?TopicID=13&StoryID=1493 (last visited June 14, 2002).
40 See Brazil's Bill on "Access to Genetic Resources," Decreto No. 306 de
19.09.1995, art. 5 (Nov. 19, 1997) (trans. By Vanira Tavares) (outlining provisions
for access to genetic resources and their derived products), at http://lbaecology.gsfc.
nasa.gov/lbaeco/ Invest/docs/genetic resourcesbill.htm (last visited June 22,
2002).
41 See id. ch. III, art. 5(11) (recognizing the national sovereignty of Brazil over
their genetic resources and derived products on its territory).
42 See id. Title IV, ch. I, art. 14 (stating that access to genetic resources in
Brazil shall be subject to prior government authorization and to the signing of a
contract between the government and the foreign object, and establishing that the
government of Brazil must keep a reference file of the contract negotiations).
43 See id. Title IV, ch. I, sec. I, art. 15 (outlining that, "to obtain authorization
and sign a contract of access to a genetic resource, the petitioner or the agency of
access must present a detailed petition, together with the project of access," as well
as "complete information on the timetable, budget, and sources of financing for the
activities," detailed and specific description of the genetic resources to which ac-
cess is intended, their current and potential uses and detailed description of the
collection systems and tools to be used, precise location of the areas where the
procedures of access will be carried on, and an indication of the destination of the
material collected and of its probable future use).
9
PACE INT'L L. REV. [Vol. 15:247
activities to the geographic area and natural resources defined
in the contract. 44 The petitioner, the government agency, the
providers of traditional knowledge, and the other parties to the
additional contracts negotiate mutually agreeable terms for the
sharing of benefits. 45 A special fund from the collected money
goes to the conservation, research, and inventory of genetic pat-
rimony.46 Access to genetic resources without authorization
constitutes a crime subject to imprisonment and a fine of up to
10,000 times the daily fine.4 7 Upon ratification, this law will
control the access to biological material and its export abroad,
as well as equitable remuneration.48
The last piece of legislation concerning access to biological
resources in Brazil is the Government Provisional Decree
2052.4 9 The provisional decree constitutes the current Brazil-
ian regime for access to genetic resources; 50 however, it still
44 See id. Title IV, ch. I, sec. V, art. 34 (noting that the government must mon-
itor "compliance with the provisions of the authorization and of the contract of
access" and ensure a detailed account of the activities, and a detailed destination
of the collected samples).
45 See id. Title IV, ch. I, sec. VI, art. 35 (reporting that in addition to the pay-
ments and sharing of benefits agreement, the government must ensure a fair com-
pensation in the form of money or commercialization rights as described in the
contract of access).
46 See Brazil's Bill on Access to Genetic Resources, Decreto No. 306 de
19.09.1995, supra note 39, art. 36 (stipulating that the forms of compensation shall
form a special fund for the conservation, research, and inventory of the biological
resources to support projects related to the conservation of natural resources).
47 See id. Title IV, ch. I, sec. VI, art. 56 (acknowledging that "the acquisition
and commercialization of genetic resources and derived products," their shipment
abroad, and the use of traditional knowledge without an authorization constitute a
crime subject to imprisonment of one to four years and a fine of up to ten thousand
Brazilian currency money).
48 See FIRST NATIONAL REPORT OF BRAZIL, supra note 8, at 159-60 (explaining
that once the Draft law is passed, it will apply to biological and genetic resources
in Brazil and the government will have the right to prohibit access to endangered
species).
49 See Francisco Arcanjo, Intellectual Property Rights and Biodiversity in Bra-
zil: Conservation, Sustainable Use and Protection of the Indigenous Rights, 36-40
(Nov. 2000) (comparing the provisional decree with the Senate bill 306/95 and
stating that the provisional decree bears the same idea as the Senate bill and has
the force of a law), at http://www.gwu.edu/-ibi/minervafall20OO/Eugenio.Arcanjo.
pdf (last visited Aug. 6, 2002).
50 See id. at 36 (asserting that the provisional decree is the current decree for
access to natural resources in Brazil until the Brazilian Senate passes a perma-
nent law).
10http://digitalcommons.pace.edu/pilr/vol15/iss1/8
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awaits discussions and approval by the Brazilian Congress.51
The next subsection outlines the implementation of the Agenda
and the CBD in Switzerland.
3. National Implementation in Switzerland
Unlike Brazil, Switzerland already had permanent laws for
the protection of biodiversity52 when it ratified the CBD in No-
vember 1994. 53 For example, the 1992 Swiss fund, endowed
with fifty million Swiss Francs, contributed to the conservation
of traditional landscapes and the preservation of cultural heri-
tage.54 Switzerland has also created "red lists" and "blue lists"
of endangered plant species. 55 Red lists provide information
about the endangered status of medicinal plants, determine
what geographic sites need protection from access, and act as
an important landscape, planning tool. 56 Blue lists register
those red list species that increased in number and act as a psy-
chological counterweight to the red lists. 57
Switzerland also developed guidelines to serve as a refer-
ence for parties involved in the access to genetic resources and
the sharing of benefits.58 The country is presently implement-
ing such national guidelines to regulate access to genetic re-
51 See id. (arguing that a law becomes permanent in Brazil after an approval
by the Brazilian Senate).
52 See Swiss AGENCY FOR THE ENVIRONMENT, FORESTS AND LANDSCAPE, NA-
TIONAL REPORT OF SWITZERLAND FOR THE CONVENTION ON BIOLOGICAL DIVERSITY,
15 (1998) [hereinafter NATIONAL REPORT OF SWITZERLAND] (stating that the pre-
existing laws include the Federal Law on the Protection of Nature and the Land-
scape from 1966, the Federal Law Relating to the Protection of the Environment
from 1983, and the Federal Law on Forests from 1991), at http://www.biodiv.org/
doc/world/ch/ch-nr-ol-en.pdf (last visited Aug. 5, 2002).
53 See id. (describing the progress made in Switzerland to implement the CBD
in the country's national legislation).
54 See id. at 17 (stating that the fund commemorated the 700th anniversary of
the Swiss Confederation).
55 See id. at 18 (describing the various methods introduced in Switzerland to
protect endangered species and threatened biodiversity systems).
56 See Swiss Clearing House Mechanism Biodiversityl Red Listsf Introduc-
tion, supra note 13, at 1 (describing the significance of the red lists as they relate to
the protection of endangered medicinal plants).
57 See A. Gigon, Blue Lists: A Conservation Tool Used for Assessing the En-
hancement of Threatened Animal and Plant Species, THE Swiss BIODIVERSiTY Fo-
RUM (specifying that blue lists are used only in conjunction with the red lists), at
http://www.biodiversity.ch/ch/index.html (last visited July 20, 2002).
58 See Swiss Agency for the Environment, Forests and Landscape, Thematic
Report on Benefit-Sharing, 8-9 (2001) (discussing the need to monitor and regulate
2003]
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sources, their utilization, and the fair sharing of benefits. 59
Switzerland presented those guidelines at the Johannesburg
World Summit on Sustainable Development.60 The following
section discusses how commercial use of medicinal plants and
equitable compensation in both Brazil and Switzerland is indis-
pensable without national legislation compliant with the TRIPS
Agreement.
B. Intellectual Property Law Protection of Biodiversity
1. The TRIPS Agreement
Similar to the CBD and the Agenda, TRIPS gives its mem-
ber countries flexibility to choose the means to protect ethnobio-
logical knowledge and medicinal plant resources. 61  The
principal objective of TRIPS is to harmonize intellectual prop-
erty laws around the world.62 The agreement provides the min-
imum intellectual property standards for countries to
implement in their national legislation.63 TRIPS addresses in-
tellectual property protection through patents.64 The agree-
access to biodiversity and assure fair benefit sharing), at http://www.biodiv.org/
worldlreports.asp?t=all#S (last visited Aug. 5, 2002).
59 See id. (outlining that the guidelines provide guidance on the fair sharing of
benefits). See generally Swiss Guidelines, supra note 11 (stating that article 1.1
provides for non-discriminatory access to natural resources; article 7.2 provides
that it is necessary for the government to record collected resources and respect
the customs and traditions of the local shareholders; and article 8.3 recommends
the sharing of intellectual property rights between the local shareholders and the
explorers who commercialize natural resources).
60 See World Summit on Sustainable Development, supra note 1 (remarking
that the Johannesburg Summit focused on how countries have implemented
Agenda 21 and the CBD).
61 See TRIPS, supra note 5, art. 27.3(b) (noting that members can exclude
from patentability plants and animals, other than microorganisms, and essentially
biological processes for the production of plants, other than non-biological and mi-
crobiological processes).
62 See generally J.H. Reichman, The TRIPS Agreement Comes of Age: Conflict
or Cooperation with the Developing Countries, 32 CASE W. RES. J. INT'L L. 441
(2000) (giving an overview of the TRIPS Agreement, and considering, specifically
some of the positive achievements and negative trends in TRIPS since the incep-
tion of the TRIPS Agreement).
63 See TRIPS, supra note 5, art. 65 (providing least-developed countries until
2006, economies in transition and developing countries until 2000, and developed
countries until 1996 to comply with the TRIPS Agreement).
64 See id. art. 27 (stating that patents shall be available for any inventions,
whether products or processes, in all fields of technology, provided that they are
new, involve an inventive step, and are capable of industrial application). See gen-
12http://digitalcommons.pace.edu/pilr/vol15/iss1/8
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ment allows member states to exclude from patent protection
certain inventions.6 5 For example, countries could deny patents
for plants and animals other than microorganisms, but could
not do so for non-biological and microbiological processes re-
lated to the production of plants. 66 Member states thus have
flexibility to protect newly discovered medicinal herbs and
traditional knowledge via patents. 67 However, the language of
the agreement is ambiguous and controversial,68 and it is pres-
ently undergoing a review by the TRIPS Council of the WTO.
6 9
TRIPS fails to directly refer to the CBD and the Agenda or
to prevent countries from regulating access to their genetic re-
sources and from sharing the benefits from commercial use.
70
In addition, TRIPS lacks provisions on traditional knowledge
but allows states to protect traditional knowledge by means
erally Richard Wilson, Protection of Traditional Medicine, July 2001, at 8-10 (em-
phasizing the importance of patents for the preservation of traditional medicinal
knowledge and medicinal plants in developing countries), at http://
www.cmhealth.org/docs/wg4_paper4.pdf (last visited Aug. 10, 2002).
65 See TRIPS, supra note 5, art. 27.2 (stating that TRIPS excludes those in-
ventions from patentability to "protect human, animal, or plant life or health, or to
avoid serious prejudice to the environment").
66 See id. art. 27.3(b) (stating that members may exclude plants from
patentability).
67 See Smith, supra note 4, at 152 (discussing that TRIPS allows countries the
flexibility to decide whether to protect biological material and process with
patents).
68 See generally TRIPS, supra note 5 (defining the terms for the patentability
of plants and biological processing). However, it is unclear what is the rationale.
Id.
69 See id. art. 27.3(b) (stating that the World Trade Organization shall review
the provisions of this subparagraph four years after the date of its entry into force).
See also World Trade Organization Doha Ministerial Conference, Draft Ministerial
Declaration, WT/MIN(01)?DEC/W/1 (Nov. 14, 2001) (reporting that the work in
the TRIPS Council on these reviews should look at the relationship between the
TRIPS Agreement and the CBD, the protection of traditional knowledge and folk-
lore, and discussing that TRIPS Agreement's development objectives as defined in
article 7 should guide the TRIP Council's work), at http://docsonline.wto.org) (last
visited Aug. 1, 2002). See generally Matthew Stilwell, Review of Article 27.3(b)
Center for Int'l Envtl. Law (June 2001) (analyzing the link between the provisions
of article 27.3(b) and development, and the overlapping coverage of TRIPS and the
CBD), at http://www.ciel.org/Publications/pubtae.html (last visited Aug. 10, 2002).
70 See Symposium on Issues Confronting the World Trade System-Summary
Reports by the Moderators, July 6-7, 2001 [hereinafter Issues Confronting the
World Trade System] (discussing the issue of divergence or convergence between
the CBD and the TRIPS Agreement), at http://www.wto.org english/forums-e/
ngo-e/ngo-symp200l-repTRIPS2_e.htm (last visited Aug. 4, 2002).
13
PACE INT'L L. REV. [Vol. 15:247
other than patents. 71 Nevertheless, TRIPS seems consistent
with the developmental purposes of Agenda 21 and the CBD.7 2
In sum, TRIPS has developmental, technological, and pub-
lic purpose objectives.7 3 However, its ambiguous language in
regard to biotechnology patents complicates national implemen-
tation by member countries. 74 The following subsections dis-
cuss the implementation of TRIPS in Brazil and Switzerland in
regard to pharmaceutical biodiversity.
2. TRIPS Implementation in Brazil
The new Industrial Property Law of Brazil75 came into ef-
fect in April 1996 to comply with the minimum requirements
established by the TRIPS Agreement.76 The law appears, how-
ever, to have weaknesses, 77 specifically live organisms are not
discoveries and therefore are not patentable.78 The Industrial
Property Law of Brazil states an invention is patentable if it
meets the requirements of novelty, inventive step, and indus-
trial application.7 9 In other words, discoveries do not constitute
inventions,80 and patents are granted neither to biological
materials found in or isolated from nature nor to second medical
71 See id. (noting that TRIPS does not discuss traditional knowledge and in-
digenous people).
72 See G. Kristin Rosendal, Impacts of Overlapping International Regimes:
The Case of Biodiversity, REV. MULTILATERALISM & INT'L ORG., Jan. 1, 2001, at 36
(explaining how TRIPS and the CBD overlap because both introduce opposing reg-
ulations aimed at the same issue area), 2001 WL 23902206.
73 See TRIPS, supra note 5 (setting the general goals of TRIPS).
74 See id. art. 27.3(b) (noting that article 27.3(b) reads ambiguously).
75 See Industrial Property Law of Brazil, Law No. 9279, May 14, 1996 (outlin-
ing the amended Brazilian patent law in 1996), at http://www.inpi.gov.br/idiomas
conteudo/law.htm (last visited Aug. 2, 2002).
76 See TRIPS, supra note 5.
77 See Robert Sherwood, Intellectual Property in Developing Countries and Ju-
dicial Systems, and Economic Development (noting that the 1996 industrial prop-
erty law in Brazil introduced improvements but was not a great advance, and
discussing that the system is suffering from bureaucracy, inadequate judicial sys-
tem, and weak protection of trade secrets), at http://www.kreative.net/ ipbenefits
(last accessed Jan. 31, 2002).
78 See Industrial Property Law of Brazil, supra note 74, art. 18(11) (stating
that living organisms are not patentable).
79 See id. art. 8 (marking that "anything contrary to morality, decency, public
safety, order, and public health is not patentable"). Id. at 18(I).
80 See id. art. 10 (determining that discoveries of living organisms are not
patentable).
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uses.81 Thus, the new industrial law of Brazil does not allow
patents for biological materials isolated from nature and for
natural biological processes.8 2 Allowing patents for isolated bio-
logical matter and secondary use in Brazil could attract more
foreign investment and stimulate development of modern
biotechnology. 3
3. TRIPS Implementation in Switzerland
Switzerland adopted its new intellectual property law in
1996.84 According to the new law, inventions contrary to public
policy cannot obtain a patent.8 5 The Swiss Patent Office grants
patents for microbiological and non-biological processes,8 6 but
the Swiss patent law provides no explicit language about biolog-
ical extractions.8 7 Switzerland has recognized a "'Swiss type'
claims ... for new therapeutic uses of known molecules ....
Therefore, if a known substance has new medicinal uses, such
81 See id. art. 10(IX) (stating that all or part of natural living beings and bio-
logical materials found in nature, or isolated therefrom, including the genome or
germ plasm of any natural living being and the natural biological processes, are
not patentable).
82 See id. (noting that biological processes are not patentable under the patent
law of Brazil).
83 See Arcanjo, supra note 49, at 25 (arguing that patenting of living forms
and biological processes in Brazil could guarantee entry of private pharmaceutical
companies).
84 See Switzerland Federal Law on Patents for Inventions, supra note 14 (pro.
viding an overview of the minimum requirements to accord a filing date and the
requirements for patentability).
85 See id. art. 2(a) (excluding inventions contrary to public order and morality
from patentability).
86 See id. art. 1(a) (stating that compounds obtained through non-biological
and microbiological processes are patentable).
87 See id. (observing that the language of article l(a) is ambiguous). See also
WTO Council for Trade-Related Aspects of Intellectual Property Rights, Communi-
cation from Switzerland, IP/C/W/284 (June 15, 2001) (outlining the view of Swit-
zerland that countries should have the discretion to exclude plants from
patentability in their national laws).
88 Switzerland Federal Law on Patents for Inventions, supra note 14, art. 7(c)
(stating that substances or compounds subject of a prior right that have a new use
shall be considered new to the extent that they are intended solely for such use).
See also id. art. 8(3) (determining that if the invention concerns a process, the
effects of the patent shall extend to the immediate products of the process). See
generally A Case for 'Swiss-type' Claims in Indian Patent Act, THE HINDU, Mar. 29,
2001 (reporting that it is necessary to distinguish between a new benefit of a
known use of a known molecule and a completely new use), at http://www.hinduon-
net.comlthehindul2001/03/29/stories/0629000a.htm (last visited Aug. 10, 2002).
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inventions qualify for patent protection.8 9 For example, aspi-
rin's original use was to treat headaches. 90 Later on, it became
known that aspirin could also treat heart diseases, and there-
fore patents could protect this second medical use to stimulate
future pharmaceutical research.91
The "Swiss claim" approach is an important aspect of the
Swiss patent law because it facilitates the development of
plant-derived drugs based on traditional ethnobiological knowl-
edge, 92 and therefore a similar approach could benefit Brazil.
Patents for non-biological processes and secondary use benefit
the protection of pharmaceutical biodiversity and yield commer-
cial benefits for the country that has implemented them.93 The
following analysis will establish the framework for comparison
between the two countries.
III. ANALYSIS
Given that the international framework provides only mini-
mal standards for protection of pharmaceutical biodiversity,
this analysis section considers constitutional protection, rich-
ness of pharmaceutical biodiversity, and ethnobiological tradi-
tions in Brazil and Switzerland. While Brazil is a heaven of
pharmaceutical biodiversity, its stringent temporary laws act as
a barrier to the progress of science, and the country's present
patent protection hinders innovation.
89 See Switzerland Federal Law on Patents for Inventions, supra note 14, art.
7(c) (allowing patents for new uses of known substances).
90 See EVERSHEDS NATIONAL BIOSCIENCE GROUP, 2ND PHARMACEUTICAL USE-
THE Swiss TYPE CLAIM (Dec. 21, 2000) (explaining that the new medical use must
be completely new and not simply a modification of an existing treatment or a
better method for treating a disease), at http://www.stepc.gr/-katharak/2nd_
Pharmaceutica _use.doc (last visited Aug. 10, 2002).
91 See id. (stating that research that results in the second medical use is sig-
nificant and as such is not less worthy of patent protection).
92 See A Case for 'Swiss-type' Claims in Indian Patent Act, supra note 88 (ar-
guing that the "Swiss claim" approach is in use in Malaysia, New Zealand, Swit-
zerland, and the United States while India considers introducing it in its patent
law because of its significant advantages).
93 See supra notes 82-90 and accompanying text (outlining the benefits of
having patents for secondary use).
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A. The International Framework Only Sets Minimal
Standards
The Agenda, CBD, and TRIPS only provide the minimum
international framework for protection of biodiversity through
intellectual property, and they all require language clarifica-
tion.94 For example, the Agenda and CBD fail to specify how
benefit sharing could take place, except that negotiating parties
must reach a mutual agreement.9 5 The Agenda and CBD also
fail to explicitly refer to TRIPS 96 and remain silent on the issue
of patentable subject matter.9 7
TRIPS creates a discord between developed and developing
countries over the criteria for patentability in the field of bio-
technology and the relationship between TRIPS and CBD. 98
Developed countries support a strong protection of all bi-
otechnological innovations through patents.9 9 Developing coun-
tries, at the same time, accuse TRIPS of encouraging biopiracy
and environmental damage by allowing for patenting of biologi-
cal and non-biological processes. 100 Adequate patent protection
for biological extracts and processes, however, fosters economic
94 See Smith, supra note 4, at 152, 163 (observing that the CBD has "overly
broad standards" and that the language of article 27.3(b) is both "sweeping and
vague").
95 See INTERNATIONAL CHAMBER OF COMMERCE COMMISSION ON INTELLECTUAL
INDUSTRIAL PROPERTY, TRIPS AND THE BIODIVERSITY CONVENTION: WHAT CONFLICT
(June 28, 1999) (arguing that there is no conflict between TRIPS and the CBD), at
http://www.iccwbo. org/home/menu intellectual_property.asp (last visited Aug. 10,
2002).
96 See CBD, supra note 4, art. 16(5) (recognizing that intellectual property
rights are important for the implementation of the CBD without directly referring
to TRIPS). See also Agenda 21, supra note 3, ch. 16 (failing to incorporate intellec-
tual property protection provisions).
97 See CBD, supra note 4, art. 16(2) (favoring technology patents, but failing
to address patent subject matter). See also Agenda 21, supra note 3, ch. 15 (lack-
ing provisions on patents).
98 See Issues Confronting the World Trade System, supra note 70 (expressing
the opposing views that the two conventions overlap or that they deal with very
different issues).
99 See World Trade Organization Communication from Switzerland, supra
note 87 (highlighting that Switzerland favors an adequate protection of biotechno-
logical inventions). See also WORLD TRADE ORGANIZATION, Review of the Provisions
of Article 27.3(b): Further View of the United States, IP/C/W/209 (Oct. 3, 2000) (pro-
viding the views of the United States that a patent discovery that is isolated and
unfound in nature is patentable).
100 See TRIPS AND THE CONVENTION ON BIODIVERSITY: WHAT CONFLICT, supra
note 95 (asserting that TRIPS takes away rights given to developing countries by
20031
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growth and development and inflow of foreign investment.10 1 It
is therefore in the best interest of developing countries, like
Brazil, to adopt the developed countries' viewpoint, such as the
Swiss model, to recognize the importance of patent protection
for the biotechnology industry. 0 2 The following section consid-
ers the basis for comparison between Switzerland and Brazil.
B. Why the Swiss Model is Adaptable in Brazil
1. Constitutional Protection of Biodiversity
Brazil and Switzerland have incorporated the protection of
the environment in their constitutions.10 3 Both countries' con-
stitutions provide that a well-maintained environment is essen-
tial for a healthy way of life, 10 4 and that the government and
the community have the duty to protect the environment.' 0 5
Also, the two countries' constitutions forbid the use of gene
the CBD). While the CBD assigns sovereignty rights in the biological resources on
the territory of each country, TRIPS allows patents for those resources. See id.
101 See Kevin McCabe, The January 1999 Review of Article 27 of the TRIPS
Agreement: Diverging Views of Developed and Developing Countries Toward the
Patentability of Biotechnology, 6 J. INTELL. PROP. L. 41, 56 (1998) (stating that
TRIPS affects developed and developing countries differently).
102 See id. (outlining the views of developed and developing countries with re-
gards to the revision of TRIPS article 27.3(b)). See also Christopher Mayer, The
Brazilian Pharmaceutical Industry Goes Walking From Ipanema to Prosperity:
Will the New Intellectual Property Law Spur Domestic Investment?, 12 TEMP. INT'L
& COMP. L.J. 377, 396 (1998) (noting that if patent protection had been in place for
medicines, then sales by U.S. pharmaceutical companies in Brazil would have in-
creased by almost fifty percent).
103 See C.F. [Constitution] art. 225 (Braz.)(1988) (amended in 1993) (dedicating
one entire chapter to environmental protection), at http://www.uniwuerzburg.de/
law/br00000_.html (last visited on Aug. 10, 2002). See also Bv. CST. COST. FED.
[Constitution] arts. 73, 74, 77, 78, 120 (Switz.) (1999) (modified in 2001), at http:l!
www.swissemb.org/legallconst.pdf (last visited July 21, 2002) (addressing issues
such as protection of the environment, forests, nature and cultural heritage, and
gene technology in the non-human field).
104 See C.F. art. 225 (Braz.) (stating that all persons have right to an ecologi-
cally balanced environment). See also Bv. CST. COST. FED. art. 73 (Switz.) (noting
that the Confederation and the Cantons shall strive to establish a durable equilib-
rium between nature, in particular its capacity to renew itself).
105 See C.F. art. 225 (Braz.) (declaring that the government and the people of
Brazil must preserve and country's rich biodiversity). See also Bv. CST. COST. FED.
art. 74 (Switz.) (articulating that the Confederation has the duty to legislate on the
protection of Swiss people and their natural environment against harm and
nuisance).
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methods that endanger human life.106 Similarly, each protects
flora from extinction, 10 7 along with nature and cultural heri-
tage.108 The Brazilian and Swiss constitutions show concern
about access to and utilization of natural resources.10 9 The con-
stitutions of Brazil and Switzerland thus illustrate their effort
to preserve nature for future generations." 0
2. Richness of Pharmaceutical Biodiversity
In addition to constitutional similarities, both countries en-
joy rich pharmaceutical biodiversity. 11 Switzerland is the
home of the Swiss Alps, which are rich with conifer forests and
medicinal plants such as oleader, palm trees, and mimosa." 12
Europeans widely believe that "[i]f mountains had a home, it
would be Switzerland." 13 Switzerland is one of the countries
106 See C.F. art. 225(1)(II) (Braz.) (stating that the government of Brazil must
preserve the country's rich natural resources and must supervise entities engaged
in research and handling of genetic material). See also By. CST. COST. FED. art.
120 (Switz.) (providing that the Swiss Confederation shall legislate on the use of
genetic material of animals, plants, and other organisms, and establishing that in
doing so it shall consider the dignity and security of men, animals and the
environment).
107 See Bv. CST. COST. FED. arts. 77, 78(4) (Switz.) (stating that the government
and the people of Switzerland shall protect forests and endangered species from
extinction). See also C.F art. 225(1)(VII) (Braz.) (providing for the protection of
flora).
108 See Bv. CST. CosT. FED. art. 78 (Switz.) (stating that the Confederation
shall preserve natural, cultural, and historical monuments and should take into
account public interest). See also C.F. arts. 225(1)(II)& (VII)(4) (Braz.) (preserving
the integrity of the country's natural resources and enlisting the territories that
are part of the national patrimony).
109 See supra notes 98-100 and accompanying text (discussing how the consti-
tutions of Brazil and Switzerland demonstrate both countries' concern about the
protection of the environment).
110 See generally supra notes 101-107 and accompanying text (analyzing the
constitutional biodiversity legal protection in Brazil and Switzerland).
111 See id. See infra notes 112-23 and accompanying text (comparing richness
of pharmaceutical biodiversity in Brazil and Switzerland).
112 See Swiss Agency for the Environment, Forests and Landscape, Clearing
House Mechanism Biodiversity Switzerland at a Glance/ Geography /Alps-The
Swiss Alps (mentioning that forests in the Alps include mainly conifer trees above
1,000 meters), at http://www.buwal.ch/nachh/chm/e/ch/geo/ geo-alps.htm (last vis-
ited Aug. 7, 2002).
113 A Summer Holiday in the Alps, DEUTSCHE PRESSE-AGENTUR [MUNICH],
June 11, 2002 (highlighting that the Alps are a special region of culture and na-
ture), LEXIS, News Group File.
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with the highest biodiversity in Europe. 114 Switzerland's bi-
odiversity protection is exemplary because the country has im-
plemented restrictive laws and the Swiss deeply care about
their country's natural resources. 115 The Alps are among the
few large wildlife areas within Europe that continue to stay un-
touched by industrial development. 1 6
Brazil also possesses some of the most diverse and rich eco-
systems in the world." 7 The Brazilian Amazon rainforest occu-
pies eighty percent of the South American Amazon and
comprises sixty-seven percent of the world's tropical forests." 8
The Brazilian Amazon includes twenty-two percent of the
known plant species in the world"19 and fifty percent of the
world's biodiversity. 20 Unlike Switzerland, Brazil has serious
conservation problems. The Brazilian Amazon rainforest suf-
fers from ecological destruction. 12
114 See Bernhard Schmidt, State and Development of Biodiversity in Switzer-
land, Institut ffir Umweltwissenshaften (stating that Switzerland is one of the Eu-
ropean countries with the highest biodiversity), at http://www.biodiversity.ch.ch.
index.html (last visited Aug. 5, 2002).
115 See id. (observing that Swiss people recognize the unique natural heritage
of the Alps since an early age).
116 See id. (asserting that Switzerland is perhaps the only country in the world
with a high population density, large economic activities, and rich biodiversity).
117 See Sturm, supra note 27 (discussing the rich biodiversity in the Brazilian
rainforest). See also Charles Clover, Drugs Companies Are Told To Pay for Plant
'Plundering,' THE DAILY TELEGRAPH (LONDON), Apr. 18, 2002 (reporting that trade
in medicinal plant products is worth 23 billion British pounds per year, and assert-
ing that drugs and perfumes companies plunder plants in developing countries
without paying compensation to the countries where those natural resources origi-
nate), LEXIS, News Group File.
118 See Amazonia in Numbers (providing biodiversity data about the Brazilian
Amazon rainforest), at http://www.bioamazonia.org.br/numerose.htm (last visited
Aug. 1, 2002). See also FIRST NATIONAL REPORT OF BRAZIL, supra note 8, at 12-13
(estimating the value of biodiversity in Brazil to be much higher than the country's
GDP).
119 See Amazonia in Numbers, supra note 118 (noting that the Brazilian Ama-
zon forest contains somewhere around one-forth of the world's plants).
120 See Corazza, supra note 9, at 1 (discussing the plague of biodiversity in the
Brazilian rainforest). The Brazilian Amazon forest has thirty percent of all the
superior plants in the world. See id. International companies exploit the natural
resources of the Brazilian Amazon forest for profitable purposes. See id.
121 See Reuters News Service, Axel Bugge, Brazil Amazon Destruction Down
But Still Alarming, PLANET ARK, June 13, 2002 (mentioning that the rate of forest
destruction in the Brazilian rainforest worries environmentalists), at http://
www.planetark.org/dailynewsstory.cfm/newsid/16404/story.htm (last visited Aug.
5, 2002). See also Janelle Kellman, The Brazilian Legal Tradition and Environ-
mental Protection: Friend or Foe, 25 HASTINGS INT'L & CoMP. L. REV. 145, 148
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In 2000, the Brazilian Amazon was 7,037 square miles and
by 2001, logging and fires destroyed 6,095 square miles. 122 Fur-
thermore, a government development plan, including infra-
structure projects, could destroy forty-two percent of the
Amazon if it progresses as promised. 123 While, both Switzer-
land and Brazil are rich in medicinal plant resources, biopiracy
in Brazil is flourishing at a large scale and resources leave the
country without compensation because of the lack of permanent
law on access to genetic resources.1 24
3. Ethnobiological Traditions
Wild medicinal plants are an important source of medicines
for eighty percent of the developing world.' 25 By consulting
traditional medicinal knowledge, researchers for new medicinal
drugs can increase the success ratio in drug trials from one suc-
cess in ten thousand samples to one success in two samples. 26
Switzerland is one such country that has solid historical tradi-
tions in ethnobiological medicine. 27
(2002) (discussing that agricultural uses and road building are among the main
factors behind the depletion of the Amazon forest).
122 See Bugge, supra note 121 (providing information about the rate of destruc-
tion of the Amazon rainforest in Brazil from the National Institute for Space
Research).
123 See id. (highlighting that the government has a vital role to play in the
protection of the natural environment in Brazil). In 2000, fires in the rainforest
decreased due to increased government monitoring. See id.
124 See Corazza, supra note 9, at 3 (noting that a North-American company has
catalogued over 7000 Amazon plants without paying anything for their gathering).
125 See David Tilford, Saving the Blueprints: The International Legal Regime
for Plant Resources, 30 CASE W. RES. J. INT'L L. 373, 428 (1998) (arguing that the
CBD recognizes the right of developing countries to demand compensation for their
natural resources).
126 See Naomi Roht-Arriaza, Of Seeds and Shamans: The Appropriation of the
Scientific and Technical Knowledge of Indigenous and Local Communities, 17
MICH. J. INT'L L. 919, 928 (1996) (stating that consulting indigenous people could
be very important for the discovery of new plant-derived drugs). See also JoAnn
Kawell, Report on Science and Technology, NACLA REPORT ON THE AMERICAS,
Mar. 1, 2002, at 1-2 (stating that local experts are the best source of knowledge
about which plants should be screened), 2002 WL 12669949.
127 See Kimberly Johnson, The Benefits of Studying Medicinal Plants and Eth-
nobotany, BIODwERSITY AND HuMAN HEALTH (discussing that the use of medicinal
plants has a long history and people continue to use plants as a source of medicinal
cure today), at http://www.wms.org/biod/value/ medplants/med-plants2.html (last
visited Aug. 10, 2002).
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The field of medicinal chemistry and the use of medicinal
plants originated in Switzerland. 128 In Switzerland, medicinal
plants serve as traditional medicines, herbal teas, health foods,
and pharmaceuticals. 129 For instance, Adonis vernalis is a
plant with well-known medicinal properties, 130 thyme cures dry
spasmodic coughs and bronchitis,' 3' and horehound treats re-
spiratory problems and helps remove phlegm from the lung.132
Brazil is also well-known for its ethnobiological tradi-
tions. 133 Many of its plants find medicinal and cosmetic uses
based on ethnobiological knowledge. 34 For example, the Brit-
ish Body Shop uses oil extracted by the Caiapo Indians 35 to
make skin cream and shampoos,' 36 Aveda produces cosmetics
using the urucum plant, which is a vegetable bleach,137 and
Channel No. 5 uses the pau-rosa.'38 An American ethnobiolo-
128 See id. (noting that medicinal plants have had a wide use in Europe and
that the writings of Theophrastus Bombastus von Hohenheim remain a
landmark).
129 See Lucy Hoareau and Edgar DaSilva, Medicinal Plants: A Re-Emerging
Health Aid, ELECTRONIC JOURNAL OF BIOTECHNOLOGY, Aug. 15, 1999, vol. 2, No. 2
(explaining that interest in medicinal plants has re-emerged as a result of the ris-
ing costs of prescription drugs and bioprospecting of new plant-derived drugs), at
http://www.ejb.org/content/vol2/issue2/full/2/ (last visited Aug. 10, 2002).
130 See id. at 4 (mentioning that the adonis vernalis is specific to Switzerland,
Sweden, and Germany).
131 See Thyme, HEALTHNOTES ONLINE (describing the traditional medical uses
of thyme to treat bronchitis and gingivitis), at http://63.65.255.14/Thyme.htm (last
visited July 31, 2002).
132 See Horehound, HEALTHNOTES ONLINE (reporting that horehound is a cough
suppressant and a bitter digestive tonic), at http://63.65.255.4/Horehound.htm
(last visited July 31, 2002).
133 See Alesandra Dalevi, Green Piracy, BRAZIL (noting that in Brazil there is a
boom of natural medicine and that Brazil ranks second in the world after India in
the use of natural medicine for treatment), at http://www.brazil-brasil.com/cvrjul
97.htm (last visited on June 14, 2002).
134 See id., at 9 (noting that in Brazil two thousand pharmacists produce 3,000
medicinal formulas using minerals, animals, and plants).
135 See Antonio Guedes & Maria Sampaio, Genetic Resources and Traditional
Knowledge in Brazil, BRAZILIAN AGRIC. RES. CORP. Oct. 30 - Nov. 1, 2000 (stating
that about 400,000 native Indians live in Brazil today in 215 ethnic groups and
that they speak 180 different languages), at http://rO.unctad.org/trade-env/testl/
openFl.htm (last visited Mar. 14, 2003).
136 See Corazza, supra note 9, at 4 (mentioning that the Body Shop uses oil of
Brazilian nuts for its creams and shampoos).
137 See id. (noting that Aveda produces cosmetics from the plant urucum).
138 See id. (stating that pau-rosa is on the list of endangered species).
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gist exclaimed that "[elvery time a shaman dies, it is as if a li-
brary burned down." 139
In sum, Switzerland and Brazil extensively use ethnobio-
logical knowledge in their pharmaceutical and medical indus-
try: another reason why the Swiss model would be relevant in
Brazil. The next section discusses Brazil's rich ethnobiological
traditions and biodiversity and its failure to yield enough bene-
fits from the commercialization of its medicinal plants
resources.
C. Brazil: Rich in Biodiversity, but Poor Commercialization
1. A Heaven of Pharmaceutical Biodiversity
Statistics demonstrate that Brazil has the highest number
of plant species in the world, while its per capita income is one
of the lowest.140 Brazil's biodiversity serves as a rich source for
plant-derived drugs. 14 1 For instance, salegen, a medicine used
to treat xerostoma, contains active ingredients extracted from a
plant native to Northeastern Brazil that tribes have used for
generations. 142 Additionally, Brazilian found quebra-pedra is
an herb that treats hepatitis, and natural prozac, another Bra-
zilian found herb, is the main ingredient in the medicine
prozac.143 However, at the same time, Brazil receives no com-
pensation for the utilization of the natural resources.1"' The
139 Alessandra Dalevi, supra note 133, at 7 (reporting that shamans already
researched about 7000 plants before indigenous people brought to their attention
important medicinal plants). Shamans could make significant contributions to the
pharmaceutical industry. Id.
140 See Conserving Indigenous Knowledge- Integrating New Systems of Integra-
tion, UNDP, CSOPP, at 2 (comparing plant biodiversity among countries and plac-
ing Brazil on the top of the chart with 55,000 species of plants), at http://
www.undp.org/csopp/ CSO/NewFiles/dociknowledge2.html (last visited Aug. 5,
2002).
141 See supra notes 140-44 (discussing medicinal uses of Brazil's tropical
plants).
142 See Dalevi, supra note 133, at 1 (asserting that costs of researching medici-
nal plant uses are much less than the costs associated with the production of new
synthetic drugs). Salegen is a medicine produced in the United States from medic-
inal plants found in Brazil. Id.
143 See id at 2 (stating that American foreign companies that conduct biopros-
pecting in Brazil could have saved much valuable research time if they knew the
meanings behind the Indian names of the herbs).
144 See id at 2 (believing that foreign pharmaceutical companies unfairly ex-
ploit Brazil, according to Darrell Posey, Director of the Program for Traditional
2003]
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rainforest is worth $43 billion for plant-derived medicines 145
and Brazil receives less than one percent of the accrued benefits
from commercialization. 146 The main reason for the flourishing
biopiracy and bioprospecting in Brazil is the lack of adopted
permanent law on access to biodiversity. 147
In addition, dialogue among foreign scientific and business
communities and the Brazilian government is strained.148 Bio-
technology is not part of the government's agenda, and this has
had devastating consequences for the country's economic devel-
opment. 49 Foreign pharmaceutical companies and researchers
state that the lack of permanent laws decrease their interest in
working in Brazil.150 Many companies have postponed their ac-
tivities until the implementation of a permanent law regulating
access to pharmaceutical biodiversity.' 5' For example, under
an agreement signed between Novartis and BioAmazonia in
1999, Novartis promised to spend $4 million in research pro-
grams in the region. 52 In return, BioAmazonia allowed Novar-
Resource Rights at the Oxford Center for the Environment in the United Kingdom
and Researcher for the Brazilian National Council for Science and Technology).
145 See id. (stating that $5.4 billion do not go to indigenous people around the
world to compensate them for their traditional knowledge).
146 See id. (noting that Brazil receives 0.001 percent from the commercial utili-
zation of its medicinal plants).
147 See Dalevi, supra note 133, at 3 (Professor Laymert Garcia from the Uni-
versity of the Campinas in Sao Paulo saying that bioprospectors take advantage of
the lack of permanent legislation to regulate commercialization of biodiversity).
148 See Brown, supra note 39 (explaining that Brazil is the world leader in
some types of cancer research, but dialogue among industry, the scientific commu-
nity, and the government is difficult).
149 See id. (asserting that Brazil's research science is on the cutting edge and
"the potential for human medicine is huge"). However, the lack of partnership be-
tween the private and public sector in Brazil has damaging consequences for the
commercialization of Brazil's rich medical plant resources. See id.
150 See id. (highlighting that if clear rules continue to be lacking, business op-
portunities will decrease).
151 See Guedes & Sampaio, supra note 135, at 3 (stating the necessity of gui-
dance on how to implement the provisionary law and that the National Research
Council, the government agency that previously authorized international scien-
tists to collect genetic resources, awaits a clarification of the rules).
152 See Brown, supra note 39 (assessing that the outcome of the Novartis deal
has negative consequences for the future development of the biotechnology sector
in Brazil). As a result, there are many designed projects, but little investment.
See id. For instance, FIR Capital Partners, a small biotechnology company in Bra-
zil, has a $75 million investment fund and plans to spend one-third of it for bio-
technology projects. See id. However, the firm is reluctant because the
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tis to ship 10,000 gene samples to Switzerland. 153 However,
BioAmazonia revoked the agreement, accused Novartis of bi-
opiracy, and cancelled the contract.154 Novartis stated its in-
tent to no longer develop projects in Brazil because the country
lacks permanent laws regulating access to pharmaceutical bi-
odiversity and the Brazilian government fails to enforce its con-
tractual obligations. 155 Thus, the lack of permanent laws on
access to biological resources and the inability to enforce con-
tracts create a disincentive among foreign companies to explore
Brazil's rich pharmaceutical biodiversity for new medicinal
drug development. 156 This is detrimental to Brazil because the
country lacks enough researchers and national infrastructure to
benefit from commercial uses of its biodiversity.
57
2. A Barrier to Progress of Science
The provisional decree in Brazil hinders international
scientists from exploring the rainforest and researching medici-
nal plants for new drug development.' 58 Research permits and
access and research restrictions cause scientists to reconsider
government of Brazil lacks consistency in its actions and permanent biodiversity
laws do not exist in Brazil. See id.
153 See id. (estimating that other companies will also remain reluctant to sign
contracts in Brazil, because the Brazilian government fails to enforce contracts).
154 See Brown, supra note 39 (detailing that a board member of BioAmazonia
denounced the contract and the government of Brazil cancelled the deal under the
growing pressure from environmental groups).
155 See id. (quoting the CEO of Novartis Pharma that Novartis "would not con-
tribute a nickel" toward the Biotechnology Center in the Amazon). See also Larry
Rohter, Brazil Moves to Protect Jungle Plants from Foreign Biopiracy, N.Y. TIMES,
Dec. 23, 2001, Al, at 4, col. 3 (reporting that many pharmaceutical companies and
laboratories hesitate to sign bioprospecting agreements in Brazil after the Novar-
tis contract failed apart), LEXIS, News Group File.
156 See supra notes 138-53 and accompanying text (demonstrating that foreign
companies express no interest in signing cooperation agreements with the Brazil-
ian government because laws in Brazil constantly change and it is difficult to over-
come the mutual distrust between foreign researchers and the Brazilian
government).
157 See Geoff Dyer, Brazilians Hope to Turn Plants into Profits: Biotechnology
Can Make Money from the Rainforest, but Will Any of the Profits Stay in the Coun-
try?, FIN. TIMES (LONDON), Aug. 28, 2001, at 8 (assessing that the value of Brazil's
biodiversity is about $2 trillion, nearly four times Brazil's annual GDP), LEXIS,
News Group File.
158 See Andrew Revkin, Biologists Sought a Treaty; Now They Fought It, N.Y.
TIMES, May 7, 2002, at F1 (observing that the CBD seriously impedes biologists'
efforts to explore new biological resources), LEXIS, News Group File.
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work in the Amazon forest and to leave thousands of plants un-
known and unused for potentially vital medicines to cure such
diseases as HIV/AIDS. 159 The problem is significant when re-
searchers in other countries need samples of natural plants to
work on their doctoral dissertations and lack permission to ship
plant samples to their laboratories. 160
Moreover, nationalist movements in Brazil hinder the ac-
cess of international scientists to the rainforest. 161 The Brazil-
ian military demarcates indigenous areas to protect the
rainforest from foreign invasion, which is disastrous for re-
searchers who collect samples and search for unknown plants
with rare medicinal value.162 The increased number of criminal
charges against foreign scientists also creates a disincentive
among foreign scientists to participate in research expeditions
in the Amazon rainforest. 163 Harsh visa restrictions, national-
ist tension, and severe criminal penalties in Brazil act as seri-
ous barriers for world renown scientists to undertake research
159 See id. (giving an example how criminal penalties might be severe, and ex-
plaining that the Federal Police of Brazil arrested an American scientist who stud-
ied the Amazon forest and seized his collection even though he had all the
necessary visas).
160 See id. (mentioning that a German botanist pursuing a science doctorate
degree at Yale University studied plants in the Brazilian Amazon when regional
newspapers announced that she was collecting genetic material in order to develop
new drugs). The resulting difficulties forced her to abandon her research. See id.
161 See Dalevi, supra note 133, at 11 (mentioning that the military of Brazil
keeps foreigners out of the Amazon). See also Mark Stevenson, China, Brazil, In-
dia, 9 Other Nations Form Alliance Against Biopiracy, ASSOCIATED PRESS, Feb. 18,
2002 (reporting that the new alliance against biopiracy would like to see more
equal trade rules on patenting and a fairer benefit-sharing mechanism), LEXIS,
News Group File.
162 See Dalevi, supra note 133, at 11 (stating that the nationalist movement
believe that the entry of foreign scientists in the Amazon forests is against the
country's national security and indicating that their motto is "Fight for the
Forest").
163 See Biopiracy in Brazil (noting that Selva Viva, an NGO created by a Swiss
citizen, was brought to court by the local Roman Catholic Church in Brazil for
illegally stealing indigenous knowledge, and discussing that this criminal case re-
sulted from a law implemented in the state of Acre, which protects biodiversity
and imposes harsh penalties against foreigners who claim rights in the Amazon
forest), at http://www.dmac.co.uk/ gen/a-sbio.html (last visited Aug. 9, 2002).
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missions that could lead to the discovery of new drugs of global
significance. 1 64
3. Present Patent Protection in Brazil Hinders Innovation
Current Brazilian patent law eliminates the possibility of
patenting products extracted from medicinal plants, and, until
recently, the law excluded biological processes from patents.
165
Moreover, Brazil invests only 1.24 percent of its GDP in science
and 0.7 percent goes to Research and Development, and addi-
tionally the Ministry of Science and Education only dates back
to 1985.166 This is problematic because the biotechnology in-
dustry depends on patent law protection due to the high costs of
research, development, and commercialization. 167 For example,
it costs about $231 million to develop a drug, and patenting a
biological invention in the United States costs approximately
$80,000.168 Consequently, pharmaceutical research and devel-
opment takes place predominantly in countries with a strong
research and development sector such as Switzerland.
169
Economic studies on patents concluded that intellectual
property protection is crucial for foreign direct investment and
164 See supra notes 156-61 and accompanying text (analyzing how harsh visa
restrictions, nationalistic tension, and severe criminal penalties in Brazil hinder
innovation).
165 See FIRST NATIONAL REPORT OF BRAZIL, supra note 8, at 160 (discussing the
latest changes in the Brazilian intellectual property legislation).
166 See KEY FACTS, supra note 9 (providing statistics about Brazil's investment
in scientific research and development).
167 See Gerald Mossinghoff & Ralph Oman, The World Intellectual Property
Organization: A United Nations Success Story, 160 WORLD AFF. 104, 105 (1997)
(discussing the successes achieved by the World Intellectual Property Organiza-
tion in Geneva). See also Alan Holmer, Patent Protection is Key, USA TODAY, Oct.
29, 2001 (emphasizing that strong patents give research-based companies the in-
centives to invest the average $500 million needed to discover and develop each
new drug), at http://www.usatoday.com/ news/commentl2001-10-29-ncoppf.htm
(last visited Aug. 10, 2002). See generally John Baremore, Don't Shoot the Messen-
ger: Congress and the Prospect of Patent Harmonization, 44 Loy. L. REV. 761
(1999) (stating that a nation's patent law is its cornerstone for economic
development).
168 See Verma, supra note 2, at 4 (highlighting that intellectual property rights
protection is crucial for investment decisions of businesses).
169 See Stevenson, supra note 15, at 1152 (emphasizing that trade secrets could
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development.170 About eighty percent of the firms in the study
testified that strong patent protection is important for invest-
ment in research and development in developing countries, and
that Brazil has weak patent protection. 171 Furthermore, bio-
technology is an industry in which wealth depends on
patents. 172
Allowing patents for natural extracts from medicinal plants
would accrue more local benefits to Brazil.173 The country
should view its genetic resources as a common heritage of man-
kind that could be a significant resource to produce life-saving,
plant-derived medicines for the benefit of the entire world.1 74
After all, since the Swiss model is relevant in Brazil, the Ama-
zon country may refer to it for guidance on how to effectively
protect its pharmaceutical biodiversity.
IV. RECOMMENDATIONS
This Part recommends that Brazil increase access of inter-
national scientists to its medicinal plants and regulate ecotour-
170 See Edwin Mansfield, Intellectual Property Protection, Foreign Direct In-
vestment, and Technology Transfer, at 21 (presenting empirical evidence between
the respect and disrespect for patents by the developing countries and foreign di-
rect investment flow by developed countries to those developing countries), at
http://www.ifc.org/economics/ pubs/discuss.htm (last visited Aug. 11, 2002).
171 See id. (concluding that strong patent protection fosters larger foreign di-
rect investment). See also Keith Maskus, Intellectual Property Rights and Eco-
nomic Development, 32 CASE W. RES. J. INT'L L. 471, 494 (2000) (discussing that
intellectual property protection is very important for development; however, the
cost of administration and enforcement of intellectual property rights could be bur-
densome as developing countries implement stronger intellectual property
systems).
172 See John Thomas, An Examination of the Issues Surrounding Biotechnology
Patenting and Its Effect Upon Entrepreneurial Companies, CRS REPORT FOR CON-
GRESS, Aug. 31, 2000, at 7 (noting that the biotechnology industry is known for the
heavy expenditures on research and development and a reliance on patent
protection).
173 See Viana, supra note 8 (stating that data from the National Institute of
Industrial Property in Brazil demonstrates that in 1999, after the 1996 Patent
Law came into effect, the number of patents granted in the biotechnology pharma-
ceutical industry has risen on average twenty percent a year).
174 See WORLD HEALTH ORGANIZATION, WORLD HEALTH ORGANIZATION
MEDICINE STRATEGY 2002-2005 (2002) (discussing the widespread use of tradi-
tional medicine and ethnobiological knowledge, the international legal framework
for access to traditional medicine, as well as the international and national re-
sources for traditional medicine), at http://www.who.int/medicines/ library/trm/
trmstrat-eng.pdf (last visited Aug. 11, 2002).
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ism, adopt the "Swiss claim" patents, and incorporate the listing
of endangered herbs.
A. Make Medicinal Plants More Accessible to Scientists and
Regulate Ecotourism
The Brazilian law on access to genetic resources limits the
access of international scientists to medicinal plants in the Am-
azon jungle. 175 As a result of the long process to obtain a scien-
tific permit in order to access the resources and the criminal
penalties, scientists prefer not to conduct research in the Brazil-
ian forests. 176 Brazil should still continue to control access to
its resources and their commercialization; however, the coun-
try's Draft Law should introduce less cumbersome restric-
tions.177 The Draft Law should reduce the wait period to obtain
a permit to less than one year, and it should allow scientists to
keep the collected samples against fair compensation.17 8
The Draft Law should take into account the Swiss guide-
lines for access to biological material. 7 9 The Brazilian Draft
Law should incorporate the following provisions from the Draft
Guidelines of Switzerland.18 0 The law should implement an ob-
jective access to the country's medicinal plant resources to reas-
sure researchers that their rejection to Brazil's genetic
resources is not discriminatory and arbitrary.' 8 ' In addition,
Brazil should remove the requirement to perform research and
development in Brazil because pharmaceutical companies gen-
erally keep their know-how in their headquarters in order to
protect their intellectual property assets from appropriation
175 See Revkin, supra note 158, at F1 (adding that in 2000, Brazil stopped ex-
ports of biological samples from the Amazon forest even to Brazilians working
abroad).
176 See id., at F1 (reporting that a researcher from Singapore abandoned a pro-
ject in the Brazilian Amazon and moved his research to a different country, where
he received better treatment).
177 See Swiss Guidelines, supra note 11, art. 3(1) (favoring a fair and equitable
sharing of genetic resources).
178 See id. art. 11(2) (noting that the government should issue access permits
within a reasonable time and should facilitate access to genetic resources).
179 See id. arts. 6, 7, 8 (including guidelines about responsibilities of users and
providers during and after the research process).
180 See id. See infra notes 181-83 and accompanying text (recommending that
the provisions from the Swiss guidelines could be pertinent to Brazil).
181 See Swiss Guidelines, supra note 11, art. 1(1) (denoting that access to natu-
ral resources should be non-discriminatory).
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abroad.18 2 Decisions about access to the genetic resources could
result in twenty days because if it takes too long, as in Brazil,
researchers could change their dissertation topics and conduct
research in countries that offer more speedy access to genetic
resources.18 3 Sharing of intellectual property assets should be
permissive because otherwise pharmaceutical companies would
be skeptical about investing in the Brazilian Amazon.18 4 In ad-
dition, a mediator should resolve differences and help avoid bi-
ased Brazilian courts. 8 5
Furthermore, ecotourism should become part of the Draft
Law before Brazil increases its use.' 8 6 The Brazilian govern-
ment has already drafted guidelines for a national ecotourism
policy and Brazil has a vast heritage for ecotourism.' 8 7 The
guidelines should require, as the Swiss policy, an environmen-
tal assessment before the access to the natural resources takes
place and should become part of the Draft Law for access to ge-
netic material. 188 Researchers entering Brazil under the Draft
Law should be required to comply with environmentally sound
methods for access to the medicinal plant resources. 8 9 This is
especially important because presently foreign tourists use
ecotourism to obtain access to Brazil's medicinal plants for bi-
oprospecting purposes.1 90
182 See id. art. 7(4) (noting that the Swiss guidelines do not require that foreign
companies perform their research in Switzerland).
183 See id. arts. 10, 11, 12 (noting that donors should cooperate with other
stakeholders to foster collaboration in the collection of genetic resources).
184 See id. arts. 8(2), 8(3) (highlighting that sharing of intellectual property
assets is not a requirement).
185 See id. art. 15(1) (encouraging the use of a mediator during the negotiation
of mutually agreeable contract terms).
186 See id. See infra notes 187-88 and accompanying text (outlining how
ecotourism should become part of the draft law in Brazil).
187 See FIRST NATIONAL REPORT OF BRAZIL, supra note 8, at 181 (discussing the
use of ecotourism in Brazil).
188 See Laurie Goering, Brazil Wants Cut of Biotech Firms' Jungle Plunder,
TRIB. COMPANY, July 6, 1999 (stating that tourists take away plants and act as
biopirates in the Amazon), at http://forests.org/archive/brazil/biotechs.htm (last
visited Aug. 5, 2002).
189 See supra notes 186-88 and accompanying text (implying the importance of
ecotourism for the protection of the environment).
190 See Mae-Wan Ho, Brazilian Shamans Denounce Biopiracy, ISIS NEWS, no.
13/14, Feb. 2002 (discussing the increasing concern among indigenous people in
Brazil about biopiracy), at http://www.i-sis.org.uk/isisnews/I-sisnewsl3-16.php
(last visited Aug. 10, 2002). See also Corazza, supra note 9 (reporting that bi-
opirates arrive on tourist visas and that it is not easy to catch them).
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Ecotourism finds wide uses in Switzerland and people are
becoming increasingly aware of the need to preserve the natural
and cultural landscape. 191 For example, the Swiss Confedera-
tion has limited transportation to certain tourism areas to pro-
tect the natural resources and new projects for transport access
are subject to environmental impact assessment. 192 It has also
issued guidelines for managing conflicts between tourism and
biological diversity.193 Switzerland urges tourists to contribute
to the survival of ecosystems, respect human dignity, choose
sustainable mobility, and participate in civil society during
their travel. 194
Similar to Switzerland, Brazil should make its proposed
Draft Law less restrictive and more aware of ecotourism. 195
This would likely assist Brazil to attract more internationally
renown scientists and accrue benefits from commercialization.
The next section discusses how it would be advantageous to
Brazil to grant patent protection to secondary uses.
B. Protect Biodiversity Through the "Swiss claim" Patent
Approach
Brazil would protect its medicinal plants and stimulate
pharmaceutical companies to research for new medicinal uses
of already discovered drugs if it adopts the "Swiss claim" ap-
proach as Switzerland.1 96 As a result, Brazilian and foreign
191 See NATIONAL REPORT OF SWITZERLAND, supra note 52, at 39-42 (mentioning
that tourism in Switzerland ranks third in exports and one person out of eleven
works in the field of tourism).
192 See "Code of Conduct" to Rein in Tourists, Save the Earth, DEUTSCHE
PRESSE-AGENTUR, May 22, 2002 (stating that Switzerland, Austria, and Germany
are the three countries "world champions of travel"), LEXIS, News Group File.
193 See NATIONAL REPORT OF SWITZERLAND, supra note 52, at 39 (discussing the
government objectives to adapt regional tourism to the ecological and landscape
problems).
194 See "Code of Conduct" to Rein in Tourists, Save the Earth, supra note 192
(stating that principles of ecotourism apply equally in rich and poor countries).
Tourism guidelines are necessary since the number of tourists in Europe and Latin
America is expected to double over the next decade. Id.
195 See Valerie Boisvert & Armelle Caron, The Convention on Biodiversity: An
Institutionalist Perspective of the Debates, 39 J. ECON. ISSUES 1, Mar. 1, 2002, at 11
(arguing that the current restrictions on access to biological material in Brazil
have their limits and stating that those measures would further increase the
problems), 2002 WL 17669311.
196 See supra notes 80-89 (explaining how the "Swiss claim" approach works in
Switzerland and its advantages). See generally Teresa Scasa, Patents for Second
2003]
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pharmaceutical companies would have an incentive to search
for secondary cures from already discovered and patented
drugs. 197 This would also encourage clinical research and new
uses in Brazil for traditional medicines. 198 For instance, "Swiss
claim" patents in Switzerland have increased the research and
development of biotechnology companies in biotechnology in-
vestment. 199 The "Swiss claim" type could possibly discover
several uses in just one medicinal plant in Brazil and save time
for scientists in terms of searching for new medicinal plants for
genetic material. 200 Otherwise, investment in new pharmaceu-
tical research would further diminish because without patent
protection for secondary uses, researchers have little incentive
to investigate the properties of existing pharmaceuticals in or-
der to determine any unknown medical uses.20' The "Swiss
claim" approach could therefore benefit the medicinal plant pro-
tection and drug development in Brazil. 202
Medical Indications and Their Potential Impact on Pharmacare in Canada, 9
HEALTH L.J. 23 (2001) (discussing that "Swiss type" claims have been adopted in
Switzerland, the United States, the United Kingdom, Sweden, and Germany).
197 See A Case for "Swiss-type" Claims in Indian Patent Act, supra note 88 (dis-
cussing how the "Swiss claim" patents work).
198 See id. (discussing the significance of "Swiss claim" patents).
199 See ROLF AUF DER MAUR, INTRODUCTION TO SWISS INTELLECTUAL PROPERTY
LAW 22, (vol. 3 (1995)) (providing a brief overview of Swiss copyright, patent,
trademark, conflicts of law, and civil procedure laws), available at http://www.
baerkarrer.ch/ 4publications/4_3_3cont.html (last visited Aug. 11, 2002).
200 See supra notes 195-199 (implying the significance of "Swiss claim" patents
to protect environmental resources). See also Jane Calvert & Greg Lynch, The
Swiss-Style Claim Saga- Is this the End?, PATENT PROSE, Jan./Feb. 2000 (mention-
ing that "Swiss type" patents are favorable to scientists and companies involved in
research to find new medical uses for compounds already known to have pharma-
ceutical properties), at http://www.bsw.com/articles22.html (last visited Aug. 10,
2002).
201 See Patents for Methods of Medical Treatment of Humans (emphasizing
that a "Swiss claim" enables second medical uses to obtain patent protection), at
http://www.med.govt.nz/buslt/intprop/patentsreview/patentsreview-
09.html#P556_133581 (last visited Aug. 10, 2002).
202 See id. (asserting that in the absence of "Swiss claim" patents, discoverers
of second medical have no incentive to invest in second medical uses, because cost
of research is high and benefits are low).
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C. Red and Blue List the Endangered Herbs in the New
Database
Brazil should regulate access to endangered herbs as is the
practice in Switzerland. 203 "Red lists" provide information
about the endangered status of Swiss medicinal plants and
landscape planning.204 In addition, "blue lists" complement the
red lists to monitor stabilization and increase of plant re-
sources. 20 5 The use of red lists and blue lists has been espe-
cially successful in northern Switzerland, where red list
findings tended to depress people, while blue lists encouraged
decision-makers and the public to increase their nature conser-
vation efforts.206
Brazil recently has created a centralized databank to store
knowledge accumulated by local indigenous people. 207 This col-
lection of traditional knowledge and medicinal plants would
provide information to patent offices about prior art 208 and
would be helpful for sharing the benefits between indigenous
people and scientists. 209 Brazil has already mapped three hun-
dred medicinal plant species. 210 A red list specification of
203 See Swiss Clearing House Mechanism Biodiversity / Red Listsf Introduc-
tion, supra note 13 (discussing that Switzerland has introduced the red lists for
endangered species and is presently implementing a red book on tourism).
204 See id. (explaining that red lists provide information about endangered
species).
205 See Gigon, supra note 57 (analyzing the significance of the blue lists to in-
crease efforts to protect the environment).
206 See id. (describing the positive effect of the concurrent use of red and blue
lists in Switzerland).
207 See Brazil Sees Promise in Jungle Plants, But Tribes See Peril, supra note
39 (noting that Brazil recently created a centralized bank to store traditional
knowledge and explaining that to use that information a researcher must pay
fees).
208 See Industrial Property Law of Brazil, supra note 75, art. 11(1) (stating
that an invention is not new if it comprises everything made available to the pub-
lic, by means of written or oral description, or in any other way before the filing
date of the patent application).
209 See Caroline Ryan, Patent to Protect Ancient Knowledge, BBC NEWS, Feb.
19, 2002 (stating that the Indian government created a Traditional Knowledge
Digital Library to record traditional treatments and prevent them from being pat-
ented as novel ideas, and that this new creation could be a model for countries in
Latin America), at http://news.bbc.co.uk (last visited Feb. 19, 2002).
21o See Brazil to Map Potential Medicinal Plants, REUTERS, Feb. 25, 2002 (stat-
ing that IBAMA has created the database of medicinal plants to prevent commer-
cial use of the plants outside Brazil), at http://www.ictsd.org/biores/02-03-07/in
brief.htm (last visited June 12, 2002).
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plants in the Brazilian database would enable the government
of Brazil to stay abreast of what species are decreasing in num-
bers. 211 In addition, use of blue lists should help maintain na-
ture conservation efforts as in Switzerland. 212 Consequently,
the Brazilian government should regulate shipping of samples
abroad, determine access to the Amazon rainforest, and monitor
landscape planning. 213
V. CONCLUSION
Brazil is a haven of pharmaceutical biodiversity, but its
lack of permanent legislation on access to medicinal plants acts
as a barrier to progress of international science, and its present
patent law hinders innovation. 21 4 Instead, Brazil could attract
foreign scientists by adapting its Draft Law to the Swiss guide-
lines for access to biological resources and by passing a perma-
nent law on access to genetic resources that is fair to foreign
researchers. 21 5 Brazil should provide patent protection for sec-
ondary uses of already patented plant-derived medicines to en-
courage the continuance of trials on already patented
medicines. 21 6 Since ecotourism could be an easy excuse for bi-
opiracy, the Brazilian government should also consider includ-
ing ecotourism in its Draft Law on access to biological
resources. 217 Finally, the Swiss method of red and blue listing
would be a good addition to the recently created Brazilian
databank system to keep track of endangered medicinal plants
in the Amazon. 218
211 See supra notes 180-83 (implying that red list classification could work well
in Brazil).
212 See supra notes 182-83 (highlighting that blue lists in Brazil could en-
courage decision-makers and the public to improve further their nature conserva-
tion efforts).
213 See id. (deducing that the positive effects of red lists in Switzerland could
apply in Brazil).
214 See supra notes 129-60 (analyzing why Brazil presently does not yield bene-
fits from the commercialization of its medicinal plant resources).
215 See supra notes 161-77 and accompanying text (recommending that Brazil
make its medicinal plants more accessible to scientists).
216 See supra notes 189-93 and accompanying text (recommending that Swit-
zerland adopt the "Swiss claim" patents).
217 See supra notes 171-76 and accompanying text (encouraging Brazil to incor-
porate ecotourism clauses in its draft law).
218 See supra notes 180-90 and accompanying text (suggesting that "red lists"
could be vital for protection of pharmaceutical biodiversity in Brazil).
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Brazil has much to learn from Switzerland since the two
countries share significant similarities in their constitutional
protection of biodiversity, richness of medicinal plants, and
ethnobiological traditions. 219 The Swiss model should assist
Brazil in protecting medicinal plant resources and managing
plants' commercial use in a way that would return economic
benefit to Brazil.220
219 See supra notes 95-128 and accompanying text (establishing the basis for
comparison between Brazil and Switzerland and why the Swiss model could be
adaptable in Brazil).
220 See Michael Huft, Indigenous Peoples and Drug Discovery Research: A
Question of Intellectual Property Rights, 89 Nw. U.L. REV. 1678, 1690-91 (1995)
(stating that during the last decade medicinal plants have become an important
source for plant-derived drugs to treat various forms of cancer).
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